HTGM - HTGM STOCK NEWS

HTG Molecular Diagnostics has expanded the HTG Transcriptome Panel (HTP) to include additional sample types beyond oncology, such as normal FFPE and PAXgene blood-based samples. This expansion enables broader applications in fields like immunology and infectious diseases. The HTP is now validated for Illumina's full range of sequencers, enhancing efficiency and reducing costs for large-scale studies. Following its August 2021 launch, HTG recognized $1 million in revenue from HTP. This innovation aims to improve precision medicine by profiling approximately 20,000 mRNA targets, aiding drug discovery and biomarker identification.

HTG Molecular Diagnostics announces the appointment of Dr. Jerald Radich to its Therapeutics Scientific Advisory Board. A leading expert in leukemia research, Dr. Radich brings extensive experience in cancer diagnostics and therapeutics. His expertise will support HTG's goal of advancing precision medicine through innovative technologies such as the HTG Transcriptome Panel. The company aims to uncover new factors affecting treatment responses in chronic and acute myeloid leukemias, enhancing their drug discovery process.

HTG Molecular Diagnostics (Nasdaq: HTGM) announces it has surpassed $1 million in revenue from its HTG Transcriptome Panel (HTP) as of November 30, 2021, following its launch in August 2021. The HTP technology is designed for disease profiling and biomarker discovery, measuring approximately 20,000 mRNA targets. Revenue comes from 16% of HTG’s customer base, with 50% generated from biopharma customers. The company highlights positive feedback regarding low sample requirements and high accuracy, aiming for further collaborations in precision medicine.

HTG Molecular Diagnostics has announced a research collaboration with the Icahn School of Medicine at Mount Sinai to utilize its innovative Transcriptome Panel technology in bladder cancer studies. This partnership involves HTG providing laboratory services using its HTG EdgeSeq technology across three clinical study cohorts. The studies aim to identify transcriptional signatures that could predict treatment outcomes for bladder cancer patients. HTG's technology is noted for its efficiency in handling degraded RNA samples, potentially transforming research methodologies.

HTG Molecular Diagnostics (NASDAQ: HTGM) announced on November 9, 2021, that its Compensation Committee granted stock options for 80,000 shares and 30,000 restricted stock units (RSUs) to two new employees. The stock options have an exercise price of $5.20 per share, matching HTG's closing price on the grant date. The options vest over four years, while RSUs vest in eight quarterly installments, both contingent on continued employment. These grants are in accordance with Nasdaq Listing Rule 5635(c)(4) and are part of HTG’s 2021 Inducement Plan.

HTG Molecular Diagnostics (HTGM) reported a 42% increase in total revenue for Q3 2021, reaching $2.5 million compared to $1.8 million in Q3 2020. Product revenue rose by 48%, attributed to increased instrument sales and recovering sample processing. Despite a net loss of $4.2 million, an improvement from last year’s $5.2 million, cash reserves stood at $25.4 million. The company announced the formation of HTG Therapeutics to enhance drug discovery through advanced RNA profiling. A conference call is scheduled for today at 4:30 PM ET.

HTG Molecular Diagnostics (Nasdaq: HTGM) announced it will report its Q3 financial results on November 10, 2021, after market close. Management will hold a conference call at 4:30 pm ET to discuss the results and provide a corporate update. HTG is focused on advancing precision medicine through its transcriptome-wide technology, aiming to enhance translational research and clinical diagnostics across various diseases. The company has established partnerships with biopharma leaders and academic institutes to innovate its RNA platform technologies.

HTG Molecular Diagnostics announces the appointment of Stephen Barat, Ph.D. as Senior Vice President of Therapeutics, expanding its drug development team. With a proven track record of launching over 15 products, Dr. Barat aims to leverage HTG's proprietary RNA platform to enhance drug discovery. Alongside him, Todd Huffman, Ph.D., Carl Kaub, and Desmond Raitt, Ph.D. join the team in key strategic roles. HTG focuses on advancing precision medicine, aiming for increased efficacy and safety in drug development.

HTG Molecular Diagnostics will present a fireside chat at Cantor Fitzgerald’s Virtual Global Healthcare Conference from September 27-30, 2021. The chat is scheduled for September 30 at 2:00 PM Eastern / 11:00 AM Pacific. Management will also hold 1x1 meetings during the conference. The company focuses on advancing precision medicine through transcriptome-wide profiling for various disease areas. Interested participants can access the webcast here.